Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Company Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Key Stats

• Today's Range: $0.13 to $0.16
• 50-Day Range: $0.07 to $0.22
• 52-Week Range: $0.06 to $0.24
• Volume: 53,391 shs
• Average Volume: 79,441 shs
• Market Capitalization: $10.76 million
• P/E Ratio: 14.51
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Enzon Pharmaceuticals Stock Analysis - MarketRank™

Enzon Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Enzon Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Enzon Pharmaceuticals is 14.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enzon Pharmaceuticals is 14.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.08.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Enzon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Enzon Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enzon Pharmaceuticals has recently increased by 406.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enzon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Enzon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of Enzon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Enzon Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enzon Pharmaceuticals has recently increased by 406.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Enzon Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Enzon Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enzon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.40% of the stock of Enzon Pharmaceuticals is held by insiders.

ENZN Stock Analysis - Frequently Asked Questions

How have ENZN shares performed this year?

Enzon Pharmaceuticals' stock was trading at $0.1561 at the start of the year. Since then, ENZN stock has decreased by 7.1% and is now trading at $0.1450.
View the best growth stocks for 2025 here.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) released its quarterly earnings data on Thursday, April, 30th. The biotechnology company reported ($0.01) EPS for the quarter.

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enzon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

• Last Earnings: 4/30/2020
• Today: 1/22/2025
• Next Earnings (Estimated): 3/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ENZN
• Previous Symbol: NASDAQ:ENZN
• CUSIP: 29390410
• CIK: 727510
• Web: www.enzon.com
• Phone: (732) 980-4500
• Fax: 732-980-4585
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.01
• Trailing P/E Ratio: 14.51
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.37 million
• Net Margins: N/A
• Pretax Margin: 5,103.85%
• Return on Equity: 48.32%
• Return on Assets: 3.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 107.24
• Quick Ratio: 107.24

Sales & Book Value

• Annual Sales: $30,000.00
• Price / Sales: 358.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 74,210,000
• Free Float: 73,918,000
• Market Cap: $10.76 million
• Optionable: Not Optionable
• Beta: 0.27